Early phase clinical trials of dual IL-7 and CCL19-armored CAR T-cell have reported preliminary evidence of anti-tumor activity and no grade >2 toxicities (198, 199), although further studies will be needed to confirm clinical benefit. This evidence concerns the gene CCL19 and neoplasm.